Diabetes management company ALR Technologies SG Ltd (OTC: ALRTF) announced on Monday that it has completed internal manufacturing testing of its GluCurve Pet CGM, confirming accuracy comparable to leading veterinary Blood Glucose Meters (BGM). The company plans to relaunch the device in the Canadian market in January 2026.

GluCurve is the first continuous glucose monitoring system specifically designed for cats and dogs. The sensor attaches painlessly to pets and provides blood sugar readings every three minutes for up to 14 days. Data is accessible to pet owners via the GluCurve app and to veterinarians through the ALRT Veterinary Web Portal, enabling remote or in-clinic insulin management.

An independent non-inferiority study is scheduled for mid-December to further validate GluCurve's efficacy against standard veterinary BGMs.

A US relaunch is expected in early Q2 2026 via a strategic veterinary distributor, followed by global expansion to Europe, Australia, Asia and South America.

ALR Technologies also offers the ALRT Diabetes Solution for human patients, combining FDA-cleared glucose monitoring, predictive A1C tracking, and an insulin dosing adjustment program to optimise diabetes therapy. The GluCurve Pet CGM extends this data-driven approach to companion animals, supporting veterinarians in optimising insulin treatment and improving diabetic care outcomes for pets.